About Caristo Diagnostics
Caristo Diagnostics is a global leader in cardiovascular disease diagnostics and risk prediction, spun out from the University of Oxford. The company has developed CaRi-Heart®, a breakthrough AI technology that analyzes routine coronary computed tomography angiography (CCTA) scans to visualize and quantify coronary inflammation—the otherwise invisible disease mechanism responsible for many fatal heart attacks and strokes. The technology applies advanced AI algorithms to standard cardiac CT imaging to detect inflammation that traditional imaging methods cannot see, transforming CCTA from a diagnostic tool into a powerful prevention platform. Caristo's flagship product includes the FAI-Score™ for inflammation measurement, CaRi-Plaque™ Analysis for plaque assessment, and an Individualised Risk Score that outperforms traditional risk prediction models. The technology has been validated in landmark clinical studies including the ORFAN registry, the world's largest coronary CT registry with 40,000+ patients, published in The Lancet. Results demonstrate that CaRi-Heart can predict fatal and non-fatal cardiac events at least 10 years in advance, even in patients without obstructive coronary artery disease. The company serves clinicians, health systems, pharmaceutical companies conducting clinical trials, and patients seeking advanced cardiac risk assessment. CaRi-Heart technology is currently in clinical use across the UK, European Union, and Australia, with investigational use status in the United States.
Mission & Story
Founding Story
Caristo Diagnostics was spun out from the University of Oxford, building on cardiovascular research conducted at the university.
Clinical Focus
Medical conditions and clinical areas addressed by Caristo Diagnostics.
Who It Serves
Milestones & Awards
Recent Milestones
Selected as World Economic Forum 2026 Technology Pioneer (June 2026). Appointed Stephen Deitsch as CEO (April 2026). Published landmark ORFAN study results in The Lancet (May 2024). FDA 510(k) clearance for CaRi-Plaque™ [K242240]. Featured in 'Super Agers' book by Dr. Eric Topol.
Awards & Recognition
World Economic Forum 2026 Technology Pioneer. Featured in Dr. Eric Topol's 'Super Agers' book as part of multimodal AI approach for heart disease prevention.
Key Partnerships
Company Details
- Headquarters
- Oxford, United Kingdom
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.